Cardiac Fibrosis - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
62 Pages - GMD12049
$2,000.00

Summary

Global Markets Direct’s, ‘Cardiac Fibrosis - Pipeline Review, H1 2014’, provides an overview of the Cardiac Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cardiac Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Cardiac Fibrosis - Overview 8
Pipeline Products for Cardiac Fibrosis - Comparative Analysis 9
Cardiac Fibrosis - Therapeutics under Development by Companies 10
Cardiac Fibrosis - Therapeutics under Investigation by Universities/Institutes 12
Cardiac Fibrosis - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Cardiac Fibrosis - Products under Development by Companies 16
Cardiac Fibrosis - Products under Investigation by Universities/Institutes 17
Cardiac Fibrosis - Companies Involved in Therapeutics Development 18
Merck & Co., Inc. 18
BioLineRx, Ltd. 19
Compugen Ltd. 20
Digna Biotech, S.L. 21
Promedior, Inc. 22
miRagen Therapeutics, Inc. 23
Fibrotech Therapeutics Pty. Ltd. 24
vida therapeutics inc. 25
CCRP Therapeutics GmbH 26
Cardiac Fibrosis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 37
Drug Profiles 39
CARD-024 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
P-17 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
disitertide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CGEN-856 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PRM-151 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MGN-4220 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PN1-Ab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
FT-011 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Therapy For End-Organ Damage - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TM-5441 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CGEN-856S - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Drug for Fibrotic Diseases - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CYP11B2 Inhibitor Program - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cardiac Fibrosis - Recent Pipeline Updates 56
Cardiac Fibrosis - Dormant Projects 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products under Development for Cardiac Fibrosis, H1 2014 8
Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Cardiac Fibrosis - Pipeline by Merck & Co., Inc., H1 2014 18
Cardiac Fibrosis - Pipeline by BioLineRx, Ltd., H1 2014 19
Cardiac Fibrosis - Pipeline by Compugen Ltd., H1 2014 20
Cardiac Fibrosis - Pipeline by Digna Biotech, S.L., H1 2014 21
Cardiac Fibrosis - Pipeline by Promedior, Inc., H1 2014 22
Cardiac Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2014 23
Cardiac Fibrosis - Pipeline by Fibrotech Therapeutics Pty. Ltd., H1 2014 24
Cardiac Fibrosis - Pipeline by vida therapeutics inc., H1 2014 25
Cardiac Fibrosis - Pipeline by CCRP Therapeutics GmbH, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 36
Number of Products by Stage and Molecule Type, H1 2014 38
Cardiac Fibrosis Therapeutics - Recent Pipeline Updates, H1 2014 56
Cardiac Fibrosis - Dormant Projects, H1 2014 60

List of Figures
Number of Products under Development for Cardiac Fibrosis, H1 2014 8
Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 37
Number of Products by Stage and Top 10 Molecule Type, H1 2014 38

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax